- Home
- SBFM vs ALZN Comparison
SBFM vs ALZN Comparison
Compare SBFM & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- ALZN
- Stock Information
- Founded
- SBFM 2006
- ALZN 2016
- Country
- SBFM United States
- ALZN United States
- Employees
- SBFM N/A
- ALZN N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- SBFM Health Care
- ALZN Health Care
- Exchange
- SBFM Nasdaq
- ALZN Nasdaq
- Market Cap
- SBFM 6.6M
- ALZN 7.5M
- IPO Year
- SBFM N/A
- ALZN 2021
- Fundamental
- Price
- SBFM $1.39
- ALZN $2.36
- Analyst Decision
- SBFM Strong Buy
- ALZN Strong Buy
- Analyst Count
- SBFM 1
- ALZN 1
- Target Price
- SBFM $15.00
- ALZN $45.00
- AVG Volume (30 Days)
- SBFM 47.2K
- ALZN 67.7K
- Earning Date
- SBFM 11-04-2025
- ALZN 09-10-2025
- Dividend Yield
- SBFM N/A
- ALZN N/A
- EPS Growth
- SBFM N/A
- ALZN N/A
- EPS
- SBFM N/A
- ALZN N/A
- Revenue
- SBFM $36,341,741.00
- ALZN N/A
- Revenue This Year
- SBFM $32.20
- ALZN N/A
- Revenue Next Year
- SBFM $32.74
- ALZN N/A
- P/E Ratio
- SBFM N/A
- ALZN N/A
- Revenue Growth
- SBFM 19.22
- ALZN N/A
- 52 Week Low
- SBFM $1.17
- ALZN $2.06
- 52 Week High
- SBFM $3.90
- ALZN $20.25
- Technical
- Relative Strength Index (RSI)
- SBFM 44.01
- ALZN 43.04
- Support Level
- SBFM $1.35
- ALZN $2.23
- Resistance Level
- SBFM $1.45
- ALZN $2.53
- Average True Range (ATR)
- SBFM 0.07
- ALZN 0.13
- MACD
- SBFM -0.00
- ALZN 0.02
- Stochastic Oscillator
- SBFM 27.78
- ALZN 42.49
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.